Top Updates Back
株式会社Connect Afya
Connect Afya Alias
2019-01-01
Kenya
臨床検査ラボサービス
医療機器・試薬卸売
クリニック診察（STI検査・健康診断・渡航医療・不妊検査）
臨床試験支援（製薬企業・CRO）
IVD臨床性能評価
AMR診断体制構築
病理検査
ゲノム解析
次世代シーケンサーサービス
デジタルマーケティングによる集患
Nairobi, Kenya
Company name
Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
株式会社タウンズ
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Parent
CA MEDLYNKS (Medlynks By Connect Afya Medical CentreLtd.)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Subsidiary
Mitsui & Co.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance
Nagasaki University
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance
Saraya
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance
Shionogi Pharmaceutical
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance
Yamaha Motor
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance
Genesia Ventures
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Shareholder
Ikemori Venture Support
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Shareholder
MSF Capital Partners
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Shareholder
Towns
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Shareholder

9 entries
DateDescription
2018 株式会社Connect Afya設立。
2019 ナイロビに自社ラボ開設。
2020 COVID-19 PCR検査を開始。ケニア最大級の検査施設に成長。Genesia Ventures等から5,000万円調達。
2021 通期黒字化を達成。
2022 KENAS認定（ISO 15189）取得。
2023 ヤマハ発動機とプロジェクト実施。三井物産共創基金に採択。塩野義製薬とAMR診断インフラ構築プロジェクト開始（経済産業省事業として採択）。
2024 新ラボ稼働。次世代シーケンサー・病理検査機器を導入。IHC検査開始。MSFキャピタルパートナーズ、タウンズ、池森ベンチャーサポートをはじめとする複数の投資家から1.8億円の資金調達を実施。
2025 塩野義製薬・サラヤ・長崎大学と抗菌薬適正使用体制の支援に関する包括連携協定を締結。
2026 CAP認定取得に向けた準備を推進。累計検査数100,000件を突破。
+ Loaded when opened
✅
2026-09-21 18:12 (Model: ggml-org/gpt-oss-20b )
↑